SLIDE 1
Rationale for Collaboration
- Pathology-oncology partnership critical in
cancer diagnosis and precision medicine
- Oncologists and pathologists increasingly
working in clinical treatment teams
- Enhance and improve dissemination of
ASCO - CAP Collaboration Richard L. Schilsky, MD ASCO Chief Medical - - PowerPoint PPT Presentation
ASCO - CAP Collaboration Richard L. Schilsky, MD ASCO Chief Medical - - PowerPoint PPT Presentation
ASCO - CAP Collaboration Richard L. Schilsky, MD ASCO Chief Medical Officer NCCS Cancer Policy Roundtable March 31, 2015 Rationale for Collaboration Pathology-oncology partnership critical in cancer diagnosis and precision medicine
SLIDE 2
SLIDE 3
Guideline Collaborations
In Development
- Molecular Markers for the Evaluation of Colorectal
Cancer
- HER2 Testing in Gastric Cancer
Published
- Recommendations for Human Epidermal Growth Factor
Receptor 2 Testing in Breast Cancer (original guideline in 2007 and 2013 update)
- Recommendations for Immunohistochemical Testing of
Estrogen/Progesterone Receptors in Breast Cancer
SLIDE 4
Molecular Oncology Tumor Boards
- Crowd-sourced and discussion-based format
- Each case moderated by a medical oncologist and
pathologist
- Average of 24 comments per discussion thread
- 2015 Topics
- January: Colorectal (KRAS)
- February: Lung (ROS1)
- March: Breast (PIK3CA)
- April: CLL (TP53); will launch 4/22
SLIDE 5
Molecular TB Page Views
SLIDE 6
ASCO-CAP Pathology Workshop
July 10, 2015
- Lack of pathology capacity in limited resource settings a key
contributor to late diagnosis and poor patient outcomes
- Workshop to convene:
– Oncologists and pathologists from four pilot countries: Honduras, Vietnam, Uganda and Haiti – ASCO and CAP members with experience in these settings
- Objectives:
– Identify common pathology challenges and needs – Assess models for improving pathology capacity in these settings – Determine what models can be applied to pilot countries – Determine how ASCO and CAP can support these efforts
6
SLIDE 7
March 2014 Genomics Roundtable
- Goal: Ensure that cancer patients &
specialists have access to high quality genomic testing & easily understandable test results relevant to clinical decision-making
- Conveners – ASCO, CAP, & AMP
- Participants:
– Patient representatives – Diagnostic companies & commercial labs – Academic clinicians & investigators
SLIDE 8
Next Steps – Consensus Standards
- Reporting
– Sequence variants – Report components
- Specimens
– Acquisition – Storage
- Working Groups Forming
- Timelines in Development
SLIDE 9
Policy Initiatives
- Regulation of Lab-Developed Tests
– FDA regulation needed to ensure analytic & clinical validity – Oncologists rely on high-quality tests for determining appropriate treatment = high-risk test
- Companion Diagnostics Workshop
– CAP involved on planning committee & panels – Goal: Engage stakeholders to discuss ways to address situations with multiple drugs & tests in the same class
- Cancer Leadership Council
– Monthly discussions to discuss key policy & advocacy activities
SLIDE 10
Other Activities
- Cancer.Net
“Spotlight On” Pathologists blog feature
Pathologist-Generated Content and Images from MyBiopsy.org “How to Read Your Pathology Report” (future content sharing)
- Health Information Technology